找报告就上发现报告（www.fxbaogao.com），这是一个资源超级丰富的专业平台。我们的用户群体庞大，深受投资者信赖。研报内容覆盖面极广，宏观、行业、公司报告应有尽有，数量巨大。我们专注于提升您的效率，界面简单好用，技术强大，帮您迅速获取关键信息。在这里，您可以深度洞察市场，做出最精准的投资判断。
The global biopharmaceutical industry has resumed pre-COVID-19 levels of investment, pipeline activity, and launch of novel medicines. Process and technology innovations accelerated by the pandemic are being integrated across the global pipeline and implemented as operational and organizational changes that are enabling ongoing productivity gains. The report assesses trends in new drug approvals and launches, overall pipeline activity, and the number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types, and the results of research are compared to the input effort in a Clinical Development Productivity Index. This report reveals important shifts in therapeutic and geographic investments and ongoing prioritization of novel mechanisms of action, innovative development methods and accelerated regulatory pathways to optimize new therapy development and delivery to patients. The research included in this report was undertaken independently by the IQVIA Institute for Human Data Science as a public service, without industry or government funding.
